caa a22 4500 606234993 CHVBK 20210128101240.0 cr unu---uuuuu 210128e20150101xx s 000 0 eng 10.1007/s11010-014-2217-x doi (NATIONALLICENCE)springer-10.1007/s11010-014-2217-x TCRP1 contributes to cisplatin resistance by preventing Pol β degradation in lung cancer cells [Elektronische Daten] [Xiaorong Liu, Chengkun Wang, Yixue Gu, Zhijie Zhang, Guopei Zheng, Zhimin He] Cisplatin (DDP) is the first-line chemotherapy drug widely used for the treatment of lung cancer patients, whereas the majority of cancer patients will eventually show resistance to DDP. The mechanisms responsible for DDP resistance are not fully understood. Tongue cancer resistance-associated protein 1 (TCRP1) gene was recently cloned and reported to specially mediate DDP resistance in human oral squamous cell carcinoma (OSCC) cells. However, the mechanisms of TCRP1-mediated DDP resistance are far from clear, and whether TCRP1 participates in DDP resistance in lung cancer cells remains unknown. Here, we show that TCRP1 contributes to DDP resistance in lung cancer cells. Knockdown of TCRP1 sensitizes the cells to DDP and increases the DDP-induced DNA damage. We have identified that Pol β is associated with DDP resistance, and Pol β knockdown delays the repair of DDP-induced DNA damage in A549/DDP cells. We find TCRP1 interacts with Pol β in lung cancer cells. Moreover, TCRP1 knockdown decreases the level of Pol β and increases the level of its ubiquitination. These results suggest that TCRP1 contributes to DDP resistance through the prevention of Pol β degradation in lung cancer cells. These findings provide new insights into chemoresistance and may contribute to prevention and reversal of DDP resistance in treatment of lung cancer in the future. Springer Science+Business Media New York, 2014 TCRP1 nationallicence DDP resistance nationallicence Pol β nationallicence DNA repair nationallicence Liu Xiaorong Cancer Research Institute, Xiangya School of Medicine, Central South University, 410078, Changsha, China aut Wang Chengkun Affiliated Cancer Hospital and Cancer Research Institute, Guangzhou Medical University, 510095, Guangzhou, China aut Gu Yixue Affiliated Cancer Hospital and Cancer Research Institute, Guangzhou Medical University, 510095, Guangzhou, China aut Zhang Zhijie Affiliated Cancer Hospital and Cancer Research Institute, Guangzhou Medical University, 510095, Guangzhou, China aut Zheng Guopei Affiliated Cancer Hospital and Cancer Research Institute, Guangzhou Medical University, 510095, Guangzhou, China aut He Zhimin Cancer Research Institute, Xiangya School of Medicine, Central South University, 410078, Changsha, China aut Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 398/1-2(2015-01-01), 175-183 0300-8177 398:1-2<175 2015 398 11010 https://doi.org/10.1007/s11010-014-2217-x text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s11010-014-2217-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Liu Xiaorong Cancer Research Institute, Xiangya School of Medicine, Central South University, 410078, Changsha, China aut NATIONALLICENCE 700 1- Wang Chengkun Affiliated Cancer Hospital and Cancer Research Institute, Guangzhou Medical University, 510095, Guangzhou, China aut NATIONALLICENCE 700 1- Gu Yixue Affiliated Cancer Hospital and Cancer Research Institute, Guangzhou Medical University, 510095, Guangzhou, China aut NATIONALLICENCE 700 1- Zhang Zhijie Affiliated Cancer Hospital and Cancer Research Institute, Guangzhou Medical University, 510095, Guangzhou, China aut NATIONALLICENCE 700 1- Zheng Guopei Affiliated Cancer Hospital and Cancer Research Institute, Guangzhou Medical University, 510095, Guangzhou, China aut NATIONALLICENCE 700 1- He Zhimin Cancer Research Institute, Xiangya School of Medicine, Central South University, 410078, Changsha, China aut NATIONALLICENCE 773 0- Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 398/1-2(2015-01-01), 175-183 0300-8177 398:1-2<175 2015 398 11010